Prevention of the development of spontaneous hypertension in rats by captopril (SQ 14,225)

European Journal of Pharmacology

Volumn 60, Issue 2-3, 1979, Pages 131-137

  Ferrone, Ronald A ^a   Antonaccio, Michael J ^a  

^a Squibb Inst for Medical Research   (United States)

Author keywords

Captopril; Development of hypertension; Drinking; SHR

Indexed keywords

CAPTOPRIL;

ANIMAL EXPERIMENT; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; FLUID INTAKE; HYPERTENSION; ORAL DRUG ADMINISTRATION; PREVENTION; RAT;

ANIMAL; BLOOD PRESSURE; BODY WEIGHT; CAPTOPRIL; DRINKING BEHAVIOR; HEART RATE; HYPERTENSION; MALE; PROLINE; RATS; TIME FACTORS;

EID: 0018575070     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(79)90211-5     Document Type: Article

References (46)

1. Renal, but not adrenal, contribution to the acute antihypertensive action of captopril (SQ 14, 225) in spontaneously hypertensive rats
2. Effects of Captopril in animal models of hypertension
3. Long-term efficacy of captopril (SQ 14,225) in 2-kidney renal hypertensive rats
4. Effects of chronic treatment with captopril (SQ 14,225), an orally active inhibitor of angiotensin I-converting enzyme, in spontaneously hypertensive rats
5. The effects of captopril (SQ 14,225) on vascular tissue renin in spontaneously hypertensive rats (SHR) and WKY-normotensive rats (NTR): Relationship to systolic blood pressure (SBP) and plasma renin activity (PRA)
6. Partial characterization of aortic renin in the spontaneously hypertensive rat and its interrelationship with plasma renin, blood pressure and sodium balance
7. Long-term blockade of angiotensin formation in various normotensive and hypertensive rat models using converting enzyme inhibitor
8. Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients
9. Validation in awake rats of a tail-cuff method for measuring systolic pressure.
10. Renin in the spontaneously hypertensive rats
11. Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting enzyme inhibitor (SQ 14,225, captopril) in hypertension patients
12. Blood pressure response and antibody formation in spontaneously hypertension rats and normal albino rats after immunization against angiotensin II
13. The inability of infusions of angiotensin to elevate the plasma vasopressin concentration in the anesthetized dog
14. Changes in plasma levels of vasopressin and renin in response to haemorrhgae in dogs
15. The effects of SQ 14,225 on systolic blood pressure and urinary excretion of vasopressin in the developing SH rat
16. The role of a renal first factor in drinking induced by extracellular stimuli
17. Postjunctional supersensitivity and subsensitivity of excitable tissues to drugs
18. Control of aldosterone secretion in the spontaneously hypertensive rat
19. Studies of the mechanism of contralateral polyuria after renal artery stenosis
20. The Intrinsic brain iso-renin-angiotensin system in the rat: its possible role in central mechanisms of blood pressure regulation
21. Arterial wall renin and renal venous renin in the hypertensive rat
22. Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14,225 in man
23. Evidence for direct neuronal stimulation by intraventricular angiotensin II
24. Cephalic angiotensin receptors mediating drinking to systemic angiotensin II
25. Lack of increased renin-angiotensin activity in rats with spontaneous hypertension
26. Antihypertensive activity in rats of SQ 14,225, an orally active inhibitor of angiotensin converting enzyme
27. Vasopressin and angiotensin: reciprocal mechanisms controlling mesenteric conductance
28. Effects of an orally active converting-enzyme inhibitor, SQ 14,225, on pressor responses to angiotensin administered into the brain ventricles of spontaneously hypertensive rats
29. Effect of angiotensin-converting enzyme inhibitor (SQ 20,881) on the plasma concentration of angiotensin I, angiotensin II and arginine vasopressin in the dog during hemorrhagic shock
30. Central action of angiotensin in stimulating ADH release
31. Systemic and regional flow distribution in normotensive and spontaneously hypertensive rats subjected to lifetime β-adrenergic blockade
32. Role of the pressor action of angiotensin II in experimental hypertension
33. Lowering of hypertension by central saralasin in the absence of plasma renin
34. Angiotensin II infusion increases vasopressin, ACTH, and 11-hydroxycorticosteroid secretion
35. Chronic antihypertensive effects of captopril (SQ 14,225), an orally active angiotensin I-converting enzyme inhibitor, in conscious 2-kidney renal hypertensive rats
36. Captopril (SQ 14,225) (D-3-mercapto-2-methyl-propanoyl-L-proline): A novel orally active inhibitor of angiotensin-converting enzyme and antihypertensive agent
37. Effect of chronic captopril (C) on renal function and vascular reactivity in conscious Wistar-Kyoto (WKY) rats
38. Blood pressure response to central and peripheral injection of angiotensin II and 8-c-phenylglysine analogue of angiotensin II in rats with experimental hypertension
39. Renin in rats with spontaneous hypertension
40. Vasopressin release during nonhypertensive hemorrhage and angiotensin II infusion
41. Renin-angiotensin system in the spontaneously hypertensive rat
42. Central receptor sites for angiotensin-induced drinking: A critical review
43. The renin-angiotensin system in SHR — a reinvestigation
44. Centrally induced drinking: Comparison of angiotensin II-and carbachol-sensitive sites in rats
45. Automated blood pressure measurements in small animals
46. Central cadiovascular effects of SQ 14,225, an angiotensin-converting enzyme inhibitor in chloralose anesthetized cats